Related Experiment Videos
The lungs in immature infants: how important is surfactant therapy in preventing chronic lung problems?
L E Swischuk1, B P Shetty, S D John
1Department of Radiology, University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77555-0709, USA.
Insights
Premature infants receiving surfactant therapy for hyaline membrane disease showed better outcomes in larger babies. Smaller infants, despite initial improvement, faced higher risks of pulmonary edema and bronchopulmonary dysplasia.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Critical Care
Background:
- Hyaline membrane disease is a common respiratory complication in premature infants.
- Surfactant therapy is a standard treatment for hyaline membrane disease.
- The long-term effects of surfactant therapy on infant lung development require further investigation.
Purpose of the Study:
- To evaluate the response to surfactant therapy in premature infants of varying birth weights.
- To identify risk factors for developing chronic lung disease after surfactant treatment.
- To differentiate between pulmonary edema and bronchopulmonary dysplasia in treated infants.
Main Methods:
- A cohort of 75 premature infants (600-3200 g) received surfactant therapy.
- Infants were monitored with serial roentgenographic examinations.
- Clinical outcomes and respiratory complications were documented over 28 days.
Main Results:
- Larger premature infants demonstrated a better response to surfactant therapy.
- Smaller infants, despite initial lung clearing, were more susceptible to pulmonary edema.
- Smaller infants also showed a higher incidence of "bubbly lungs," indicative of bronchopulmonary dysplasia.
Conclusions:
- While surfactant therapy improves initial lung function in premature infants, smaller infants remain at significant risk for chronic lung disease.
- Pulmonary edema and bronchopulmonary dysplasia may represent distinct complications in this population.
- Further research is needed to clarify the pathogenesis and management of these conditions.
Abstract:
Seventy-five premature infants weighing between 600 and 3200 g were studied over a period of 1 year. All of the infants received surfactant therapy for hyaline membrane disease immediately after birth and, thereafter, up to four doses every 6 h. The roentgenographic findings in all patients were documented at birth and at 2 days, 7-10 days, and 21-28 days of life. Larger babies responded to surfactant therapy better than did smaller infants. The smaller infants, even after initial clearing, were prone to develop pulmonary edema and the bubbly lungs of bronchopulmonary dysplasia. These data suggest that small infants, while initially responding to surfactant therapy with clearing of their lungs, are still at considerable risk of developing chronic lung disease in the form of pulmonary edema and bronchopulmonary dysplasia. An explanation is offered for why this occurs; at the same time it is suggested that, in view of our findings and those in the literature, the problems of pulmonary edema and bubbly lungs be more clearly separated.